Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.14B P/E 106.23 EPS this Y -36.50% Ern Qtrly Grth -
Income -76.43M Forward P/E -12.24 EPS next Y -12.60% 50D Avg Chg 11.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 37.00%
Dividend N/A Price/Book 4.20 EPS next 5Y - 52W High Chg -21.00%
Recommedations 1.80 Quick Ratio 16.81 Shares Outstanding 24.68M 52W Low Chg 233.00%
Insider Own 13.38% ROA -20.05% Shares Float 13.49M Beta -
Inst Own 85.07% ROE -29.30% Shares Shorted/Prior 1.91M/1.26M Price 49.93
Gross Margin - Profit Margin - Avg. Volume 204,851 Target Price 57.11
Oper. Margin - Earnings Date May 13 Volume 127,404 Change -0.85%
About Disc Medicine, Inc.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Disc Medicine, Inc. News
04/04/24 Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
01:24 PM Disc Medicine (IRON) Down on Mixed Results From AURORA Study
04/01/24 Disc Medicine Plummets After Placebo Effect Confounds Sunlight Sensitivity Study
04/01/24 Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
03/23/24 Disc Medicine Inc (IRON) Reports Earnings: A Detailed Look at Fiscal Performance
03/21/24 Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/06/24 Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
02/26/24 Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
02/20/24 Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
02/09/24 Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
02/07/24 Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
01/03/24 Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/20/23 Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
12/15/23 Insider Sell Alert: Director William White Sells 33,511 Shares of Disc Medicine Inc (IRON)
12/11/23 Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
12/11/23 Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
12/08/23 Insider Sell Alert: CFO Joanne Bryce Sells 2,541 Shares of Disc Medicine Inc (IRON)
11/14/23 Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin
11/13/23 How Much Upside is Left in Disc Medicine, Inc. (IRON)? Wall Street Analysts Think 38.17%
11/09/23 Disc Medicine Inc (IRON) Reports Q3 2023 Financial Results and Business Progress
IRON Chatroom

User Image Lorenyk Posted - 04/30/24

$IRON Buy? or no

User Image ridhwan1820 Posted - 04/25/24

$IRON is anyone looking at Abeona Therapeutics?

User Image TruthTooPower Posted - 04/25/24

$IRON!!! StockBraker!! EXACTLY ON THAT PT!!! !!!!!!!!!!!$51!!!!!!!!!!!!!!!

User Image BioRunner9 Posted - 04/24/24

$IRON wow this is so low

User Image working_girl Posted - 04/22/24

$IRON steamy POS I am out. GL

User Image working_girl Posted - 04/20/24

$IRON <—- I found the gremlin in my account that’s bleeding 🩸🩸🩸

User Image StockBraker Posted - 04/16/24

$IRON

User Image insiderbuyingselling Posted - 04/15/24

$IRON new insider selling: 2560 shares. http://insiderbuyingselling.com/?t=IRON

User Image working_girl Posted - 04/15/24

$IRON WTF

User Image StockBraker Posted - 04/12/24

It's time to Pump some $IRON

User Image Broncos07 Posted - 04/11/24

$IRON this is what ive been waiting for… bought the dip on April 1st… like to see it do the reverse.

User Image Bananagrabber1 Posted - 04/10/24

$IRON honestly I hope this does well. I don’t have a great investment record though.. Real investors look at me the same way vampires look at count chocula.

User Image Broncos07 Posted - 04/09/24

$IRON bought the stock after it took its nose dive on the 1st. Holding until its back up to the $70 mark. Good luck all!!!! May the trading Gods shine down on you. Pic taken yesterday from Saint Albans, Vt.

User Image SalmanAziz Posted - 04/08/24

$IRON looks like it is in reversal mode. Let's add some here at 31.25 and we will ride it back over $35 bucks.

User Image erevnon Posted - 04/08/24

Stifel maintains Disc Medicine $IRON at Buy and raises the price target from $71 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image TruthTooPower Posted - 04/08/24

$IRON The Phase 2 Had A Unique Finding In The Placebo Results… the finding Icerall was a good result!

User Image ridhwan1820 Posted - 04/06/24

$IRON forget about PT. Whats the fair value given the bad news about its drug trial?

User Image Bananagrabber1 Posted - 04/05/24

$IRON

User Image StockBraker Posted - 04/05/24

$IRON Wedbush reaffirmed their outperform rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Monday morning, RTT News reports. Wedbush currently has a $43.00 price objective on the stock, down from their prior price objective of $84.00.

User Image Bananagrabber1 Posted - 04/05/24

$IRON ok!! Let’s go!

User Image Slinga_Malinga Posted - 04/05/24

$IRON this is crap

User Image working_girl Posted - 04/04/24

$IRON Definitely outperformed $SPY today lol

User Image Bananagrabber1 Posted - 04/04/24

$IRON

User Image Bananagrabber1 Posted - 04/04/24

$IRON sometimes a proud tree must wither away to make way for new life.

User Image Bananagrabber1 Posted - 04/04/24

$IRON relax people. This will be fine.

User Image Slinga_Malinga Posted - 04/04/24

$IRON go up you pos

User Image Slinga_Malinga Posted - 04/04/24

$IRON will this hit 31-32 this week

User Image PencilNeckGeek Posted - 04/04/24

$IRON yikes. Ugly drop

User Image Slinga_Malinga Posted - 04/04/24

$IRON trash

User Image Bananagrabber1 Posted - 04/04/24

$IRON I hate when on paper it’s a great risk to reward then it end up like this for some reason lol.

Analyst Ratings
Stifel Buy Apr 8, 24
Morgan Stanley Equal-Weight Apr 2, 24
BMO Capital Outperform Apr 2, 24
Stifel Buy Apr 2, 24
Raymond James Outperform Apr 1, 24
HC Wainwright & Co. Buy Apr 1, 24
HC Wainwright & Co. Buy Mar 22, 24
Stifel Buy Mar 12, 24
BMO Capital Outperform Feb 29, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bitterman Kevin Director Director Jan 23 Sell 67.65 102,500 6,934,125 198,326 01/25/24
Bitterman Kevin Director Director Jan 10 Sell 64.00 20,000 1,280,000 786,160 01/12/24
Atlas Venture Fund X, L.P. 10% Owner 10% Owner Jan 10 Sell 64 50,000 3,200,000 786,160 01/12/24
ORBIMED ADVISORS LLC Director Director Dec 18 Sell 59.24 1,724 102,130 12/20/23
ORBIMED ADVISORS LLC Director Director Dec 18 Option 38 1,724 65,512 1,724 12/20/23
Ashiya Mona Director Director Dec 18 Sell 59.24 1,724 102,130 12/20/23
Ashiya Mona Director Director Dec 18 Option 38 1,724 65,512 1,724 12/20/23
Ashiya Mona Director Director Dec 14 Sell 56.75 433,200 24,584,100 224,405 12/15/23
ORBIMED ADVISORS LLC Director Director Dec 14 Sell 56.75 433,200 24,584,100 224,405 12/15/23
Bitterman Kevin Director Director Dec 12 Sell 61.76 76,064 4,697,713 806,160 12/14/23
Atlas Venture Fund X, L.P. 10% Owner 10% Owner Dec 12 Sell 61.76 190,163 11,744,467 806,160 12/14/23
ORBIMED ADVISORS LLC Director Director Dec 12 Sell 58.95 134,200 7,911,090 727,807 12/14/23
Ashiya Mona Director Director Dec 12 Sell 58.95 134,200 7,911,090 727,807 12/14/23
Khara Rahul General Counsel General Counsel Nov 14 Sell 50.79 4,900 248,871 11/15/23
Khara Rahul General Counsel General Counsel Nov 14 Option 14.69 4,900 71,981 4,900 11/15/23
Khara Rahul General Counsel General Counsel Nov 03 Sell 50 100 5,000 11/07/23
Khara Rahul General Counsel General Counsel Nov 03 Option 14.69 100 1,469 100 11/07/23
Atlas Venture Fund X, L.P. 10% Owner 10% Owner Sep 14 Sell 53.14 357,449 18,994,840 1,593,785 09/18/23
Savage William Jacob Chief Medical Office.. Chief Medical Officer Aug 21 Option 2.65 3,000 7,950 3,000 08/22/23
Atlas Venture Fund X, L.P. 10% Owner 10% Owner Aug 14 Sell 52.92 359,000 18,998,280 882,224 08/16/23
MacDonald Brian Richard Chief Innovation Off.. Chief Innovation Officer Jun 28 Sell 47.11 15,124 712,492 12,276 06/30/23
Leonard Braden Michael 10% Owner 10% Owner Apr 11 Buy 1.41 955,000 1,346,550 5,000,000 04/13/22